Hybio Pharmaceutical (300199)

Currency in CNY
23.74
+0.56(+2.42%)
Closed·

300199 Financial Summary

Key Ratios

P/E Ratio-189.71
Price/Book25.46
Debt / Equity266.71%
Return on Equity-13.37%
Dividend Yield0.00%
EBITDA113.52M
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2015
31/12
2016
31/12
2017
31/12
2019
01/01
2019
31/12
2020
31/12
2022
01/01
2023
01/01
2023
31/12
2024
31/12
* In Millions of CNY (except for per share items)

Earnings

Latest Release
May 30, 2025
EPS / Forecast
0.08 / --
Revenue / Forecast
309.97M / --
EPS Revisions
Last 90 days

FAQ

What were Hybio Pharmaceutical's earnings for the latest quarter?

The Hybio Pharmaceutical EPS (TTM) is -0.10. Hybio Pharmaceutical reported sales of 309.97, net income of 69.87, and EPS of 0.08 for the latest quarter.

What was Hybio Pharmaceutical's net income for the latest quarter?

Hybio Pharmaceutical's net income for the latest quarter was 69.87.

How did Hybio Pharmaceutical's performance compare year-over-year in the latest quarter?

The company's revenue moved from 214.97 in the previous quarter to 309.97 in the latest quarter, and net income moved from -138.85 to 69.87 compared to the previous quarter.

What is Hybio Pharmaceutical's net profit margin on a TTM basis?

Hybio Pharmaceutical's trailing twelve months (TTM) net profit margin is -29.42%.

How does Hybio Pharmaceutical's debt to equity ratio compare to industry standards?

Hybio Pharmaceutical's total debt-to-equity ratio is 266.71%.

What is Hybio Pharmaceutical's return on investment on a TTM basis?

Hybio Pharmaceutical's trailing twelve months (TTM) return on investment (ROI) is -13.37%.

Did Hybio Pharmaceutical gain or lose cash last quarter?

In the latest quarter, Hybio Pharmaceutical's net change in cash was -38.59 million.

What were Hybio Pharmaceutical's total assets and liabilities in the latest quarter?

As of the latest quarter, Hybio Pharmaceutical reported total assets of 3,038.05 million and total liabilities of 1,592.00 million.

How has Hybio Pharmaceutical's total revenue grown this year?

Hybio Pharmaceutical's total revenue was 214.97 in the previous quarter and 309.97 in the latest quarter.

What is Hybio Pharmaceutical's gross margin on a TTM basis?

Hybio Pharmaceutical's trailing twelve months (TTM) gross margin is 53.31%.

What was Hybio Pharmaceutical's revenue per share for the latest quarter?

Hybio Pharmaceutical's revenue per share for the latest quarter was 6.97.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.